Profile data is unavailable for this security.
About the company
Marksans Pharma Limited is an India-based company, which is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two research and development centers, one located in Goa and the other in Navi Mumbai. The Company's product portfolio spreads various therapeutic segments of the cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products (over-the-counter) include pain management, upper respiratory, digestive health, vitamins, minerals and supplements (VMS) and skin care products. Its prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic.
- Revenue in INR (TTM)28.03bn
- Net income in INR3.60bn
- Incorporated1992
- Employees1.35k
- LocationMarksans Pharma Ltd21 Lotus Business Park, Off New Link Road,, Andheri (W)MUMBAI 400053IndiaIND
- Phone+91 2 240012000
- Fax+91 2 240012099
- Websitehttps://www.marksanspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supriya Lifescience Ltd | 7.35bn | 1.85bn | 53.90bn | 515.00 | 29.06 | -- | 25.51 | 7.33 | 23.05 | 23.05 | 91.47 | -- | -- | -- | -- | 14,280,700.00 | -- | 18.45 | -- | 21.63 | 72.33 | 59.62 | 25.19 | 25.45 | -- | 129.43 | -- | 3.59 | 22.11 | 17.45 | 57.80 | 20.69 | 45.94 | -- |
| F D C Ltd | 20.78bn | 2.17bn | 61.80bn | 6.86k | 28.52 | -- | 22.30 | 2.97 | 13.31 | 13.31 | 127.73 | -- | -- | -- | -- | 3,030,531.00 | -- | 11.35 | -- | 12.96 | 67.92 | 60.85 | 10.43 | 14.75 | -- | 47.92 | -- | 6.34 | 8.50 | 9.42 | -12.59 | 2.15 | 25.37 | -- |
| Blue Jet Healthcare Ltd | 10.53bn | 2.94bn | 62.78bn | 491.00 | 21.37 | -- | 19.86 | 5.96 | 16.93 | 16.93 | 60.76 | -- | -- | -- | -- | 21,448,020.00 | -- | -- | -- | -- | 53.75 | -- | 27.88 | -- | -- | 59.81 | -- | -- | 44.74 | -- | 86.38 | -- | -- | -- |
| Shilpa Medicare Ltd | 14.32bn | 1.50bn | 65.25bn | 898.00 | 43.04 | -- | 24.35 | 4.56 | 7.75 | 7.75 | 73.87 | -- | -- | -- | -- | 15,945,910.00 | -- | 2.02 | -- | 2.61 | 70.47 | 60.07 | 10.48 | 5.17 | -- | 4.67 | -- | 9.89 | 11.71 | 7.22 | 145.63 | -12.90 | 16.09 | -- |
| Aarti Pharmalabs Ltd | 18.01bn | 2.14bn | 65.60bn | 2.16k | 30.69 | -- | 20.98 | 3.64 | 23.58 | 23.58 | 200.27 | -- | -- | -- | -- | 8,324,436.00 | -- | -- | -- | -- | 53.87 | -- | 11.87 | -- | -- | 9.34 | -- | -- | 14.17 | -- | 25.59 | -- | -- | -- |
| Akums Drugs and Pharmaceuticals Ltd | 42.57bn | 3.18bn | 75.01bn | 7.54k | 23.58 | -- | 15.66 | 1.76 | 20.78 | 20.78 | 277.93 | -- | -- | -- | -- | 5,648,482.00 | -- | -- | -- | -- | 41.45 | -- | 7.63 | -- | -- | 4.15 | -- | -- | -1.44 | -- | 8,481.07 | -- | -- | -- |
| Sudeep Pharma Ltd | 6.17bn | 1.68bn | 75.27bn | -- | 43.72 | -- | 40.98 | 12.21 | 15.24 | 15.24 | 55.94 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 63.01 | -- | 27.56 | -- | -- | 55.99 | -- | -- | 9.40 | -- | 4.19 | -- | -- | -- |
| Strides Pharma Science Ltd | 47.26bn | 5.11bn | 81.13bn | 3.30k | 15.86 | -- | 11.14 | 1.72 | 55.49 | 55.49 | 512.73 | -- | -- | -- | -- | 14,315,680.00 | -- | -0.6014 | -- | -1.09 | 59.34 | 50.33 | 11.23 | -1.06 | -- | 8.50 | -- | -- | 17.36 | 10.65 | 437.22 | 52.50 | 10.08 | -22.16 |
| Marksans Pharma Ltd | 28.03bn | 3.60bn | 82.27bn | 1.35k | 22.81 | -- | 17.93 | 2.93 | 7.96 | 7.96 | 61.92 | -- | -- | -- | -- | 20,780,450.00 | -- | 14.15 | -- | 17.41 | 56.77 | 51.56 | 12.90 | 14.58 | -- | 20.42 | -- | 7.77 | 20.46 | 18.25 | 21.32 | 26.60 | 23.73 | 51.57 |
| Procter & Gamble Health Ltd | 13.49bn | 2.93bn | 84.49bn | 1.33k | 28.82 | -- | 26.71 | 6.27 | 176.64 | 176.64 | 811.45 | -- | -- | -- | -- | 10,169,760.00 | -- | -- | -- | -- | 72.49 | -- | 21.76 | -- | -- | 806.81 | -- | -- | -- | -- | -- | -- | -- | -- |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 87.73bn | 3.76k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.29 | -- | 40.74 | -- | 92.07 | -- | 16.78 | -- | -- | -- | -- | 44.59 | 37.80 | 31.10 | 73.77 | 47.62 | -- |
| Sanofi India Ltd | 19.33bn | 3.56bn | 92.69bn | 991.00 | 26.01 | -- | 23.54 | 4.80 | 154.71 | 154.71 | 839.09 | -- | -- | -- | -- | 19,500,500.00 | -- | 22.31 | -- | 31.44 | 51.42 | 54.10 | 18.44 | 21.53 | -- | 321.27 | -- | 132.73 | 0.8567 | -8.10 | -13.96 | -5.41 | -13.65 | 1.99 |
| Sanofi Consumer Healthcare India Ltd | 8.16bn | 2.18bn | 96.26bn | 583.00 | 44.18 | -- | 42.37 | 11.79 | 94.62 | 94.62 | 354.49 | -- | -- | -- | -- | 14,003,430.00 | -- | -- | -- | -- | 75.05 | -- | 26.69 | -- | -- | 143.16 | -- | -- | 30.45 | -- | 9.76 | -- | -- | -- |
| Viyash Scientific Ltd | 21.26bn | 768.08m | 96.30bn | 1.24k | 93.00 | -- | 47.84 | 4.53 | 2.37 | 2.37 | 70.40 | -- | -- | -- | -- | 17,086,170.00 | -- | 0.4014 | -- | 0.6553 | 51.15 | 42.16 | 4.52 | 0.4199 | -- | 3.92 | -- | 995.91 | 13.26 | 5.64 | 160.99 | -20.73 | -0.126 | -- |
| Corona Remedies Ltd | 13.44bn | 1.71bn | 96.46bn | 4.57k | 56.30 | -- | 46.16 | 7.18 | 28.01 | 28.01 | 219.70 | -- | -- | -- | -- | 2,980,876.00 | -- | -- | -- | -- | 81.28 | -- | 12.75 | -- | -- | 55.10 | -- | -- | 17.93 | -- | 65.11 | -- | -- | -- |
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 110.89bn | 2.20k | 20.43 | -- | 18.04 | 4.41 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
Data as of Feb 18 2026. Currency figures normalised to Marksans Pharma Ltd's reporting currency: Indian Rupee INR
9.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jan 2026 | 10.74m | 2.37% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 7.83m | 1.73% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 5.37m | 1.19% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Jan 2026 | 5.13m | 1.13% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 3.59m | 0.79% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 3.34m | 0.74% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 2.47m | 0.55% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 2.44m | 0.54% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 884.79k | 0.20% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 747.08k | 0.17% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
